In fiscal 2026, which ended Apr 30, 2026, Pharmacyte Biotech, Inc. used $5.2 million of cash from operations, down 73.0% from the year before. The company returned $401,625 in share buybacks to shareholders.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 30, 2026
|
FY 2025
Apr 30, 2025
|
FY 2024
Apr 30, 2024
|
FY 2023
Apr 30, 2023
|
FY 2022
Apr 30, 2022
|
FY 2021
Apr 30, 2021
|
FY 2020
Apr 30, 2020
|
FY 2019
Apr 30, 2019
|
FY 2018
Apr 30, 2018
|
FY 2013
Apr 30, 2013
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||
| Depreciation and amortization |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
-100.0%
|
| Stock-based compensation |
—
|
1
|
0
-100.0%
|
1
+9099.5%
|
0
-77.9%
|
0
-82.9%
|
0
-47.3%
|
0
+25.7%
|
0
-49.5%
|
1
+38.0%
|
0
-100.0%
|
| Operating cash flow |
-4
+14.3%
|
-5
-73.0%
|
-3
-38.4%
|
-2
+43.3%
|
-4
+7.9%
|
-4
-23.6%
|
-3
-42.4%
|
-2
+18.7%
|
-3
+43.3%
|
-5
|
-0
-50.6%
|
| Investing | |||||||||||
| Investing cash flow |
—
|
2
+128.6%
|
-7
-40.0%
|
-5
|
0
|
0
|
0
|
0
|
0
|
0
|
-1
+25.8%
|
| Financing | |||||||||||
| Debt repaid |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
|
| Short-term debt issued |
—
|
—
|
—
|
—
|
—
|
—
|
0
|
—
|
—
|
—
|
—
|
| Stock buybacks |
—
|
0
-84.2%
|
3
-91.0%
|
28
+107.9%
|
14
|
—
|
—
|
—
|
—
|
—
|
—
|
| Financing cash flow |
6
+143.7%
|
7
+126.3%
|
-25
-133.7%
|
-11
+21.0%
|
-14
-115.5%
|
87
+1783.0%
|
5
+70.1%
|
3
+16.4%
|
2
-12.6%
|
3
|
1
+12.0%
|
| Change in cash | |||||||||||
| Effect of exchange rate |
0
+658.6%
|
0
+958.4%
|
-0
+29.5%
|
-0
+93.0%
|
-0
|
—
|
—
|
—
|
—
|
—
|
—
|
| Net change in cash |
5
+123.4%
|
3
+109.8%
|
-35
-96.0%
|
-18
-2.9%
|
-17
-120.9%
|
83
+6264.4%
|
1
|
—
|
—
|
—
|
—
|
| Shareholder returns | |||||||||||
| Returned to shareholders |
—
|
0
|
3
|
28
|
14
|
—
|
—
|
—
|
—
|
—
|
—
|
| Ratios | |||||||||||
| Stock-based compensation to revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.00%
|
| Cash conversion |
—
|
—
|
-0.10x
|
-6.45x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.